Ivermectina para COVID-19 (18 feb. 2021) | Buenos Aires; IECS; 18 feb. 2021. | LILACS | BRISA

Main content 1 Search 2 Footer 3

+A A -A High contrast

Ivermectina para COVID-19 (18 feb. 2021) / Ivermectina para COVID-19 (18 Feb. 2021)

Instituto de Efectividad Clínica y Sanitaria.

Buenos Aires; IECS; 18 feb. 2021.

Non-conventional in Es | LILACS, BRISA | ID: biblio-1151761

Responsible library: BR1.1

Subject(s)

Pneumonia, Viral/drug therapy; Ivermectin/therapeutic use; Coronavirus Infections/drug therapy; Betacoronavirus/drug effects; Technology Assessment, Biomedical; Health Evaluation; Cost-Benefit Analysis

Search on Google

Full text: 1 Index: LILACS Main subject: Pneumonia, Viral / Ivermectin / Coronavirus Infections / Betacoronavirus Type of study: Evaluation_studies / Health_technology_assessment Language: Es Year: 2021 Type: Non-conventional

Search on Google

Full text: 1 Index: LILACS Main subject: Pneumonia, Viral / Ivermectin / Coronavirus Infections / Betacoronavirus Type of study: Evaluation_studies / Health_technology_assessment Language: Es Year: 2021 Type: Non-conventional